Citation for published version


DOI

Link to record in KAR

http://kar.kent.ac.uk/62223/

Document Version

Author's Accepted Manuscript

Copyright & reuse
Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder.

Versions of research
The version in the Kent Academic Repository may differ from the final published version. Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the published version of record.

Enquiries
For any further enquiries regarding the licence status of this document, please contact: researchsupport@kent.ac.uk
If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at http://kar.kent.ac.uk/contact.html
What is Karyomapping and where does it fit in the world of preimplantation genetic diagnosis (PGD)?

Authors:
Darren K. Griffin
Rebecca L. Gould

School of Biological Sciences,
University of Kent,
Canterbury CT2 7NJ. UK

The Bridge Centre, 1 St
Thomas St, London, SE1
9RY. UK

Abstract
The first application of preimplantation genetic diagnosis (PGD) recently celebrated its 25th birthday. Aside from the very early days when chromosomal diagnoses were used (by sexing) for the selective implantation of embryos unaffected by sex linked disorders, the paths of chromosomal and monogenic PGD have diverged. For monogenic disorders, progress has been impeded by the need to tailor each diagnosis to the mutation in question. For chromosomal diagnoses, fluorescent in situ hybridization (FISH) technology was replaced by array comparative genomic hybridization (aCGH), and then next generation sequencing (NGS). Karyomapping is a novel approach that allows the detection of the inheritance of (grand) parental haploblocks through the identification of inherited chromosomal segments. It involves genome-wide single nucleotide polymorphism (SNP) analysis of parental DNA, a reference from a related individual of known disease status (typically an affected child) and amplified DNA form biopsied cells of the (usually blastocyst) embryos in question. Identification of informative loci for each of four parental haplotypes is followed by direct comparison to the reference, ultimately creating a Karyomap. The Karyomapping programme (Illumina) displays homologous chromosomes, points of crossing over and the haplotype of each of the embryos. It also detects meiotic trisomy, monosomy, triploidy and uniparental heterodisomy (some of which NGS and aCGH will not). Inherent in the design is the analysis of “key SNPs” (heterozygous informative calls) thereby avoiding the risk of misdiagnoses caused by the phenomenon of allele drop out (ADO). Karyomapping is currently in use for the detection of monogenic disorders and around 1000 clinics offer it worldwide making use of about 20 diagnostic laboratories. At the time of writing, over two and a half thousand clinical cases have been performed. Because of the limited detection of some post-zygotic errors such as post-zygotic trisomy which can also lead to mosaicism, Karyomapping has not yet been fully applied clinically for aneuploidy screening. The diagnostic potential of the technique will be fully recognised with the application of this technology on clinical cases.
1. A brief history of PGD

Preimplantation genetic diagnosis (PGD) involves the genetic testing of oocytes or IVF embryos facilitating selective transfer of apparently genetically normal embryos [Handyside, 2011]. PGD collectively refers to the diagnosis of monogenic disorders, human leukocyte antigen (HLA) typing, detection of unbalanced chromosome rearrangements ahead of implantation to reduce the risk of babies born with congenital abnormalities or implantation failure and/or pregnancy loss [Braude et al., 2002] [Frumkin et al., 2008] [Harton et al., 2011b]. The first reported case of PGD in non-human species was sex selection of rabbits performed by Bob Edwards and Richard Gardner [Gardner and Edwards, 1968]. In 1990, the first clinical cases in humans were performed for two couples at risk of transmitting X-linked-Adrenoleukodystrophy (X-ALD) and X-linked mental retardation [Handyside et al., 1990] with the use of sex-chromosome specific primers. Later the first PGD for an autosomal recessive monogenic disorder (Cystic Fibrosis, ΔF508 mutation of the CFTR gene) was announced (in 1992) [Handyside et al., 1992]. As previously alluded to, PGD has come to refer not only the detection of specific monogenic traits but also the elimination of chromosomally unbalanced products from rearrangement carriers and the selection of human leukocyte antigen (HLA) identical embryos which might serve as potential ‘saviour siblings’ for affected individuals in need of bone-marrow transfer [Kahraman et al., 2014]. In contrast, preimplantation genetic screening (PGS), sometimes referred to as PGD-A, specifically pertains to aneuploidy assessment in embryos e.g. for referral categories such as advanced maternal age, recurrent implantation failure or recurrent miscarriage [Delhanty et al., 1993] [Geraedts and De Wert, 2009] [Geraedts, 2010] [Harper and SenGupta, 2012b] [Traeger-Synodinos and Staessen, 2014]. PGD can be applied to detect any single gene mutation, but the “headline” diseases tend to be cystic fibrosis, beta-thalassemia, myotonic dystrophy, Huntington’s disease and fragile X [Harper and SenGupta, 2012b] [Spits and Sermon, 2009]. However, the ‘holy grail’ of PGD is a single universal test that will detect any monogenic and all chromosomal disorders simultaneously [Handyside, 2015] [Thornhill et al., 2015].

Historically, it was the development of polymerase chain reaction (PCR) to be sensitive enough to work on single cells that heralded techniques for mutation detection in this setting [Ben-Nagi et al., 2016] [Handyside et al., 2004] [Thornhill and Snow, 2002]. The inherent problems associated with such diagnostic tests however lie in their sensitivity and in the issue of contamination. In terms of sensitivity, the tiny amount of DNA (5–10 pg) present in a single cell that needs to be analysed raises problems of amplification failure and allele drop out (ADO) (i.e. allele specific amplification that could lead to a heterozygote being diagnosed as a homozygote). Regarding contamination, all precautions must be taken to ensure that no amount of contaminating DNA enters the reaction tube [Thornhill and Snow, 2002]. This has been a problem from even the earliest days of PGD [Handyside et al., 1990] even when amplifying repetitive Y-specific sequences (e.g. [Chong et al., 1993] [Hashiba et al., 1999] [Levinson et al., 1995] [Nakahori et al., 1991]). Nested PCR (a second round of singleplex PCR using the first multiplex as a template) increased specificity and thus the ability to detect diseases such as cystic fibrosis and Alpha-1 Antitrypsin (A1AT) deficiency [Handyside et al., 1992]. Countless other mutations followed (e.g. [Dahdouh et al., 2015] [Hussey et al., 1999] [Liu et al., 1995] [Ray et al., 2001]).
Human genome sequencing data (International Human Genome Sequencing Consortium, 2004; Lander et al., 2001; Sachidanandam et al., 2001; Venter et al., 2001) revealed polymorphic markers that can be used in a multiplex PCR strategy (Thornhill et al., 2015). In particular, analysis of short tandem repeat (STR) markers (principally tetranucleotide repeats) facilitated analysis not only of the mutation in question but of linked markers around the gene. Such strategies minimised the problems caused by ADO and contamination as each individual analysis confirms the other (Harton et al., 2011a; Thornhill et al., 2015). The technology was taken a step further with the adoption of whole genomic amplification e.g. multiple displacement amplification (MDA) (Handyside et al., 2004; Hellani et al., 2008), facilitating multiplex PCRs and chromosome copy number detection (Dahdouh et al., 2015) – see later. PCR with fluorescently labelled primers also facilitated more accurate detection and multiplexing (Ao et al., 1998; De Rycke, 2010; Spits and Sermon, 2009).

Using this approach over a 10-year period (1997-2007) they reported that the misdiagnosis rate was 10/3727 (0.27%) (Ben-Nagi et al., 2016; Harper et al., 2012a). This also allowed for analysis of so called saviour siblings (Handyside and Xu, 2012; Renwick et al., 2010) and ultimately became the established approach for PGD (Fiorentino et al., 2004; Handyside, 2015). The main issue with this approach is that it needs to be tailored to the patients in question, leading to an inevitable (and often stressful) waiting period where primers are designed and tested for couples. Furthermore, it was limited in its ability to detect chromosome abnormalities (Ata et al., 2012; Konstantinidis et al., 2015; Munné, 2006; Munné et al., 1996; Thornhill et al., 2015).

Following the ultimately unreliable PCR sexing strategies attempts to sex preimplantation embryos (Handyside et al., 1990), attention turned to fluorescence in-situ hybridisation (FISH) using sex chromosome specific probes (Griffin et al., 1991). Clinical application followed (Griffin et al., 1994; Griffin et al., 1992; Griffin et al., 1993) from 1992-1994, 27 treatment cycles ensued, leading to 9 in and 5 female live births (Delhanty et al., 1993; Griffin et al., 1994; Griffin et al., 1993). FISH was then applied to translocation detection and aneuploidy screening (Munné et al., 1996; Munné and Cohen, 1993; 1998; Munné et al., 1994) and became the most common form of PGD. Referral categories were advanced maternal age (AMA), recurrent miscarriage (RM), recurrent implantation failure (RIF) and severe male factor infertility. The approach made use of fluorescent probes chiefly for chromosomes 13, 16, 18, 21, 22 (X and Y) (Munné et al., 1996; Munné and Cohen, 1993; 1998; Munné et al., 1994) but was the subject of controversy in the field (Summers and Poland, 2009), with randomized controlled trials indicating no clear benefit for using it. It is now a matter of historical record that one study (Mastenbroek et al., 2007) provided evidence that there was a detrimental effect of PGS, with others demonstrating no benefit (Blockeel et al., 2008; Debrock et al., 2010; Hardarson et al., 2008; Jansen et al., 2008; Mersereau et al., 2008; Meyer et al., 2009; Schoolcraft et al., 2009; Staessen et al., 2008), and 5-7 colour FISH strategies were largely discontinued. Even though 24 chromosome FISH was successfully applied to human embryos (Ioannou et al., 2012; Ioannou et al., 2011) there were technical problems with overlapping signals, failed probes, etc. condemning FISH to being a research tool only (albeit a useful one) for looking at phenomena such as nuclear organization and mosaicism. FISH still persists in some PGD clinics however array comparative genomic hybridization (aCGH) and next generation sequencing (NGS) have largely replaced it.
Comparative genomic hybridisation (CGH) took the principles of FISH one step further, by using differentially labelled test and control (normal) DNA, that are competitively hybridized to metaphase chromosomes [Theisen, 2008]. Unlike FISH, CGH allowed for the more rapid assessment of chromosome copy number in the entire genome [Forozan et al., 1997] [Speicher et al., 1993] but was limited to a resolution of approximately 5-10Mb in most clinical applications [Kirchhoff et al., 1998] [Lichter et al., 2000]. Due to its limitations, this technology fell out of favour for clinical diagnosis, therefore other techniques were developed, including aCGH and NGS as mentioned previously.

Both aCGH and NGS require whole genome amplification strategies such as multiple displacement amplification (MDA) or degenerate oligonucleotide primed-PCR (DOP-PCR). Array CGH involves fluorescent labeling of a test DNA sample and a reference (normal) in two different fluorescent colours [De Ravel et al., 2007]. Simultaneous hybridization to a tiling path microarray precedes per-chromosome colour ratio analysis – deviations from 1:1 are indicative of aneuploidy, deletions and duplications [Fishel et al., 2010] [Le Caignec et al., 2006] [Traversa et al., 2011] [Vanneste et al., 2009]. At a similar time, Treff and colleagues developed and validated real-time quantitative PCR (RT-qPCR) [Scott et al., 2013b] [Treff and Scott, 2013b] [Treff et al., 2012]. In RT-qPCR samples undergo a pre-amplification step, followed by a high-order multiplex PCR reaction to amplify two regions on each arm of all the chromosomes. Rapid quantification of each product using RT-qPCR then allows for the evaluation of copy number over the whole genome [Dahdouh et al., 2015]. Using this technique, PCR is performed directly on the sample, without a whole genome amplification (WGA) step required in technology such as aCGH and SNP microarrays (see below). However, this means that RT-qPCR can only be used on trophectoderm samples, and so sufficient blastocyst embryos need to be available [Dahdouh et al., 2015] [Treff et al., 2012].

Around the time of the aCGH renaissance, biopsy strategies switched from cleavage stage to blastocyst stage, and aCGH has recently largely been replaced by NGS due to the availability of benchtop sequencing technology. To detect aneuploidy by this approach fragmentation of the whole genome amplified DNA into 100–200 base pairs pieces is essential. Sequencing using fluorescent tags ensues to indicate the relevant sample, facilitating low cost, high throughput analysis [Fiorentino et al., 2014]. Sequence data is compared with a reference genome and then the process involves simple “binning” and counting of sequences to generate copy number information [Fiorentino et al., 2014]. In other words, the number of sequences counted from a specific chromosome is proportional to the chromosome copy number, leading to detection of monosomy, trisomy or segmental alterations [Handyside, 2013] [Handyside and Wells, 2013]. NGS has a greater dynamic range than aCGH and represents the current state of the art for aneuploidy detection for PGD.

2. Single nucleotide polymorphism arrays (SNP chips)

Specialist microarrays detect thousands of SNPs across the genome in a range of cell types including human embryos [Handyside, 2015]. Initially developed for genome wide association studies (GWAS), SNP chips represent biallelic loci where each allele is of roughly a similar frequency [Habela and Hamosh, 2013] [LaFramboise, 2009]. Probing SNP chips leads to each allele being differentially fluorescently labelled thereby detecting homozygotes and heterozygotes and a binary readout at each
What is Karyomapping and where does it fit in the world of pre implantation genetic diagnosis (PGD)?

locus e.g. AA, AB, BB. SNPS are located mostly in non-coding regions (around 40 million are validated in the human genome) with SNP chips typically containing 660,000 to 2 million loci spread roughly evenly along the length of all human chromosomes [Dahdouh et al., 2015].

As SNPs are biallelic in nature, they are theoretically less informative than STR markers [Handyside, 2015]. However, given the information of parental genotype and a relative of known disease status, the four distinct sets of markers can be identified along the length of each parental chromosome for each tested SNPs [Handyside, 2015]. Such an approach has been used for linkage analysis for monogenic disease detection [Rabinowitz et al., 2011] and detection of chromosome abnormalities [Treff et al., 2011] [Dahdouh et al., 2015]; the Karyomapping technique combines these two strategies.

3. Karyomapping

Karyomapping [Handyside et al., 2010] determines the inheritance from the parental (or grandparental) chromosomes through the recapitulation of haploblocks or inherited chromosomal segments). The approach involves genome-wide SNP analysis of parental DNA, amplified embryo DNA and an appropriate ‘reference’ such as a close relative (typically an older, affected child is used).

The initial stage is the identification of ‘informative’ loci for each of the parental haplotypes at which where parent is homozygous and another heterozygous [Natesan et al., 2014a]. This is analogous to a “backcross” that we learn about in genetics 101. These informative loci are then compared to the reference DNA in order to establish phase (assign a reference “affected” haplotype). After this the genotype of each embryo is compared to the reference to establish similarity or difference at each informative locus. The result is a karyomap (figure 1) that displays homologous chromosomes as well as points of meiotic crossing over.

Direct comparison of the haploblock at the chromosomal locus of interest in the reference with those of each of the embryos in question (figure 1) allows the diagnosis of the presence or absence of a disease causing allele [Handyside, 2015]. This is achieved using the principles of genetic linkage established by Morgan and Sturtevant in the 1930s and does not involve direct mutation testing. One of the important advantages of Karyomapping is that it can also be applied for the diagnosis of meiotic trisomy (figure 1 right), monosomy, triploidy, parthenogenetic activation and uniparental heterodisomy; as well as patterns of genomic duplication seen in, for example, hydatidiform moles [Handyside et al., 2010] [Natesan et al., 2014a] [Natesan et al., 2014b]. When analysing the Karyomapping programme output, monosomies and segmental deletions are visualised as absence of haploblocks from one parent. Meiotic (but not post-zygotic) trisomies are visualised as both haplotypes on a section of the chromosome, reduced to homozygosité after a crossing over event. Furthermore, meiosis I and meiosis II errors can potentially be distinguished depending on whether the “double haplotype” pattern involves the centromere of the chromosome [Handyside et al., 2010]. Moreover, Karyomapping only involves the detection of heterozygous SNP calls. These are termed “key SNPs” and, by gathering the information from thousands of key SNPs, the misdiagnosis risks associated with ADO are eliminated.
What is Karyomapping and where does it fit in the world of preimplantation genetic diagnosis (PGD)?

Figure 1. Karyomapping output of the RARS2 gene on chromosome 6q15 (linked to pontocerebellar hypoplasia). From left to right, the red and blue bars (far left) are the paternal genotype, the yellow and green bars the maternal genotype. The blue and yellow bars are the reference (affected sibling), the remainder are embryonic genotypes showing (grand)parental inheritance of haploblocks. In embryo 9 (far right) the rapid alternating yellow and green bars represent a meiotic maternal trisomy (probably meiosis II as the pattern is not present around the centromere).
Karyomapping therefore facilitates the simultaneous detection of monogenic and chromosomal disorders in a single test requiring only minimal patient work up \[\text{Ben-Nagi et al., 2016; Dahdouh et al., 2015; Handyside et al., 2010}\]. When applied clinically, although Karyomapping can be used on any SNP chip with reasonable genome coverage (or in principle on NGS data) it uses exclusively a dedicated Illumina SNP chip with \~300,000 SNPs and a bespoke software suite for visualization. Karyomapping was validated using a blinded retrospective analysis by comparison with an STR marker and mutation detection approach (see above). The original studies in this regard were two case reports where Karyomapping was run in parallel with conventional analysis for Smith Lemli Opitz Syndrome and Marfan Syndrome respectively [\text{Natesan et al., 2014b; Thornhill et al., 2015}]. The first of these revealed full concordance with the clinical analysis of the samples by STR analysis and for aneuploidy testing [\text{Natesan et al., 2014a; Natesan et al., 2014b}]. The second [\text{Thornhill et al., 2015}] established that both approaches diagnosed disease status with high efficiency and accuracy but that Karyomapping was a considerably more time-efficient process given that the pre-PGD patient work-up was much shorter [\text{Thornhill et al., 2015}]. Both led to unaffected, chromosomally normal live births. A further study used Karyomapping for detection of TSC2 (tuberous sclerosis) mutations [\text{Giménez et al., 2015}]. In this case Karyomapping was able to detect the mutation whereas conventional analysis was not and led to the birth of an unaffected child. [\text{Giménez et al., 2015}]. Analysis of subsequent multiple cases compared Karyomapping with direct mutation analysis in 218 embryos from 44 IVF cycles. The authors established that Karyomapping produces the same result as mutation analysis in 213/218 (97.7\%) cases and that non-concordance was a result of consanguinity [\text{Natesan et al., 2014b}].

The potentially ubiquitous “platform independent” nature of Karyomapping infers a certain degree of “future proofing,” particularly as the output is binary i.e. a series of AA, AB and BB biallelic genotypes [\text{Giménez et al., 2015}]. It is noteworthy however, that even when we consider continually improving whole genome amplification protocols, gaps are bound to appear for technical reasons associated with the amplification from such a small template. Karyomapping has the potential to combat this problem by refining the algorithms to predict the likely genotype by further linkage analysis [\text{Giménez et al., 2015}]. In the future, there is a possibility of combining Karyomapping with allele intensity measurements for the detection of non-miotic trisomies and duplications [\text{Rabinowitz et al., 2012; Zamani Esteki et al., 2015a}] thereby distinguishing meiosis I, meiosis II and post-zygotic errors [\text{Giménez et al., 2015}]. This is clinically significant because mosaic trisomies of meiotic origin usually lead to clinical problems; however, those of post-zygotic origin can, in certain circumstances, lead to unaffected live births.

Whether we should use PGS at all still remains the topic of controversial debate; however, there is increasing evidence of its efficacy in improving IVF success and reducing the risk of miscarriage [\text{Forman et al., 2013a; Forman et al., 2013b; Giménez et al., 2015; Scott et al., 2013b; Yang et al., 2012}]. From a clinical point of view, the additional information about the origin of the chromosomal error facilitated by Karyomapping (but not other PGS strategies) has the potential to aid couples to establish future treatment regimens; donor gametes may be an option [\text{Thornhill et al., 2015}].

Despite its many advantages, Karyomapping is limited in a number of
areas. The inherent requirement of DNA from a family member with known disease status (e.g. affected sibling) particularly in dominant disorders that may shorten life span thereby (leading to such an individual not being available) is one example. Another is, if a meiotic cross over in either parent, reference individual or embryo juxtaposes the locus, this may lead to difficulties in data interpretation and thus an inconclusive diagnosis. Karyomapping will not detect de novo mutations other than those that are inherited by Mendelian pattern  [Rechitsky et al., 2011]. A final problem (hitherto already mentioned) is the fact that Karyomapping cannot easily detect post-zygotic trisomies unless combined with quantitative approaches such as NGS, aCGH or allele intensity measurement.

Although patient work up for Karyomapping is acknowledged to be shorter than that of other methods for mutation detection, disorders that are not already established by PGD technologies will need STR marker tests before Karyomapping can be used. In these cases, the work up time for Karyomapping is the same as other technologies. It is important to note that there are cost implications regarding the implementation of Karyomapping. If the lab follows the published Illumina protocol, Karyomapping requires 4 products: SureMDA™, DNA Analysis Kit, the iScan® System or NextSeq® 550 System, and BlueFuse® Multi analysis software (Illumina 2015). The scanning system required to read the BeadChips is different for those required for NGS (VeriSeq®), and Karyomapping requires MDA to amplify the DNA instead of PCR-based methods commonly used in aCGH and NGS. Due to these requirements, there is also a need for dedicated workrooms for each stage of sample preparation that adds to the logistical costs of running a Karyomapping assay.

4. Alternatives to Karyomapping

As previously mentioned, detection of both monogenic disorders and chromosomal abnormalities simultaneously is of paramount importance, therefore different methods have been developed. One suggestion is the combination of classical PGD techniques, such as STR+direct mutation analysis combined with aneuploidy testing through the use of aCGH  [Rechitsky et al., 2015]. This method was shown to increase implantation rates and significantly reduce miscarriage rates, however it requires different experimental setup leading potentially to increased time and cost within the diagnostic laboratory  [Rechitsky et al., 2015].

Treff et al. developed the use of RT-qPCR for the simultaneous detection of monogenic disorders and aneuploidy in IVF derived human embryos. This technique is based around a targeted NGS strategy and a multiplex PCR reaction that had targeted the required mutation site and chromosome-specific target sequences  [Treff et al., 2013a]. Interestingly, with this technique the necessary read depth for accurate sequencing of the mutation site is reduced per chromosome copy number, which allows for a reduction in per sample cost as well as the time required to run the test  [Dahdouh et al., 2015]. Zimmerman and colleagues determined that this strategy was more reliable than other techniques  [Zimmerman et al., 2016] with 303/304 (99.7%) embryos getting a definitive diagnosis and 1/304 (0.3%) recorded as inconclusive due to a recombination event. This study also demonstrated an 82% (27/33) pregnancy rate  [Zimmerman et al., 2016].

Another interesting method is the use of NGS technology with linkage analysis described by Yan and colleagues. This technique has been labelled “mutated allele revealed by sequencing with aneuploidy and linkage analyses” (MARSALA)  [Yan et al., 2016].
What is Karyomapping and where does it fit in the world of preimplantation genetic diagnosis (PGD)?

2015) and involves multiple annealing and looping-based amplification cycles (MALBAC) for whole-genome amplification. Aneuploidy is then detected by copy number variations (CNVs), then detection of single-nucleotide variations (SNVs) in the PCR amplified MALBAC product determines the disease status of the sample. The false-positive and false-negative SNVs are avoided by using an NGS based linkage analysis [Yan et al., 2015], and importantly this technology has been used to achieve two viable and healthy live births [Yan et al., 2015].

Haplarithmisis [Zamani Esteki, 2015b; Zamani Esteki et al., 2015a] is an extension of Karyomapping technology that allows B allele frequencies to be called as well as the standard AA, BB or AB alleles we expect from SNP data. Zamani et al. argue that the process of whole-genome amplification is in itself problematic due to the introduction of artefacts, thus other haplotyping methods suffer from error-prone SNP genotypes (AA, AB, BB) [Zamani Esteki, 2015b; Zamani Esteki et al., 2015a]. Haplarithmisis has been shown to diagnose specific disease causing alleles throughout the genome, as well as indicating the presence of numerical and structural chromosomal abnormalities in the embryos. Furthermore, it has been shown that using this technique, meiotic segregation errors can be distinguished from mitotic ones [Zamani Esteki, 2015b].

5. State of the ART

Karyomapping was first commercialized by Illumina in 2013 and is currently a routine procedure for PGD detection of single gene disorders. At time of writing (April 2017) around 1000 clinics worldwide offer karyomapping, handled largely by 20 diagnostic laboratories (personal communication from PGD international society meeting, Valencia March 2017) with ~2500 cycles currently performed. The inability to detect post-zygotic trisomy reliably however and the ever-present problem of mosaicism means that Karyomapping is not widely used yet for aneuploidy screening. Presentations at the Valencia meeting are however describing strategies of combining NGS with Karyomapping so that copy number difference (meiotic and post-zygotic) can be detected alongside monogenic defects.

Acknowledgments

The authors are grateful to Professor Alan Handyside whose genius led to the invention of Karyomapping. We are also grateful to Cagri Ogur (Istanbul) for her critical reading of the manuscript and to Matt Wyatt (Genesis Genetics) for providing the Karyomapping screenshots.
What is Karyomapping and where does it fit in the world of pre implantation genetic diagnosis (PGD)?

References


What is Karyomapping and where does it fit in the world of preimplantation genetic diagnosis (PGD)?


Geraedts, J.P. 2010. Does additional hybridization also improve preimplantation genetic screening results?


What is Karyomapping and where does it fit in the world of pre implantation genetic diagnosis (PGD)?


advanced maternal age caused a decrease in clinical pregnancy rate: a randomized controlled trial. Human reproduction. 23:2806-2812.


What is Karyomapping and where does it fit in the world of pre implantation genetic diagnosis (PGD)?


What is Karyomapping and where does it fit in the world of preimplantation genetic diagnosis (PGD)?


Rechitsky, S., T. Pakhalchuk, G. San Ramos, A. Goodman, Z. Zlatopolsky, and A. Kuliev. 2015. First systematic experience of preimplantation genetic diagnosis for
single-gene disorders, and/or preimplantation human leukocyte antigen typing, combined with 24-chromosome aneuploidy testing. Fertility and sterility. 103:503-512.


What is Karyomapping and where does it fit in the world of preimplantation genetic diagnosis (PGD)?


**Zamani Esteki, M.** 2015b. Haplarithmisis to study haplotypes genome-wide to single-cell resolution, enabling a generic method for preimplantation genetic diagnosis in the clinic and novel fundamental genome research.
